Nuclear medicine treatment cures lethal form of ovarian cancer in preclinical setting

A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the Journal of Nuclear Medicine.

AI and machine learning can successfully diagnose polycystic ovary syndrome

Artificial intelligence (AI) and machine learning (ML) can effectively detect and diagnose Polycystic Ovary Syndrome (PCOS), which is the most common hormone disorder among women, typically between ages 15 and 45, according to a new study by the National Institutes of Health. Researchers systematically reviewed published scientific studies that used AI/ML to analyze data to diagnose and classify PCOS and found that AI/ML based programs were able to successfully detect PCOS.

Personalized combination treatment turns on an immunometabolic switch to effectively control aggressive prostate cancer

Researchers at the University of Chicago Medicine Comprehensive Cancer Center established “proof-of-concept” for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

OMCAZ happy with suspension of contract to Agro Fuel

…appeals to government to consider floating a tender for local oil companies to openly participate

THE Oil Marketing Companies Association of Zambia (OMCAZ) has commended government for suspending a contract awarded to Agro Fuel Investment Limited to import three consignments of low Sulphur Diesel at a contract sum of UA$210 million.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.